FDA Approves Lumateperone sNDA With Data Showing Reduced Schizophrenia Relapse Risk
Key Clinical Summary
- The US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for lumateperone (CAPLYTA) for relapse prevention in schizophrenia.
- Lumateperone reduced relapse risk by 63% vs placebo in a phase 3 trial (hazard ratio 0.37; p = 0.0002).
- The drug also prolonged time to relapse, with 84% of patients remaining relapse-free over 6 months during double-blind treatment.
Lumateperone (CAPLYTA) has received US Food and Drug Administration (FDA) approval for relapse prevention in adults with schizophrenia, announced manufacturer Johnson & Johnson. The supplemental New Drug Application (sNDA) highlights evidence supporting sustained efficacy and tolerability in a condition marked by frequent relapse and high unmet treatment needs.
Regulatory Context
The FDA decision was supported by a multicenter, multinational phase 3 randomized withdrawal trial evaluating lumateperone 42 mg daily in adults with schizophrenia. Following an 18-week open-label stabilization phase, patients were randomized to continue lumateperone (n = 110) or switch to placebo (n = 114) for up to 26 weeks.
Lumateperone significantly prolonged time to relapse compared with placebo (p = 0.0002). The treatment reduced relapse risk by 63% (hazard ratio 0.37), with 84% of patients remaining relapse-free at 6 months. Time to all-cause discontinuation, including relapse, was also significantly delayed.
Safety findings were consistent with prior studies, with no new safety signals identified. The most common treatment-related adverse event was headache, occurring in at least 5% of patients and at twice the rate of placebo. No clinically relevant increases were observed in prolactin or cardiometabolic parameters during the double-blind phase.
Long-term data from a 12-month open-label extension showed a mean weight reduction of –2.05 kg and stability or improvement in metabolic measures. Lumateperone also demonstrated minimal impact on extrapyramidal symptoms and weight in earlier short-term studies.
Clinical Implications
Relapse remains a major clinical challenge in schizophrenia, often leading to hospitalization, functional decline, and increased caregiver burden. Adults with schizophrenia experience an average of 9 relapse episodes over 6 years, underscoring the need for durable maintenance therapies.
The demonstrated reduction in relapse risk and delay in time to relapse with lumateperone may support improved long-term outcomes. Its favorable metabolic and tolerability profile addresses common reasons for treatment discontinuation. Given that approximately 40% of individuals with schizophrenia in the US remain inadequately treated, therapies that combine efficacy with tolerability could enhance adherence.
Reducing relapse also has broader implications, including lowering the economic burden of schizophrenia, estimated at $366.8 billion in the US in 2024.
Expert Commentary
“Relapse can be one of the most disruptive aspects of schizophrenia, often undoing hard-won progress and increasing the risk of hospitalization,” said Christoph U. Correll, MD, Clinical Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell, New York, and Psych Congress faculty member, in a press release. “These phase 3 results—showing significantly longer time to relapse with 84% remaining relapse free over 6 months—provide clinicians with another tool that can offer long-term stability.”
